Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients

Author:

Lim Na Rae1ORCID,Kim Jiyoung1,Chung Woo Chul1ORCID

Affiliation:

1. Department of Internal Medicine, St. Vincent Hospital The Catholic University of Korea Suwon South Korea

Abstract

AbstractBackground/AimsHelicobacter pylori (H. pylori) infections can recur as either recrudescence or reinfection. At a time when the decline in the eradication rate is becoming evident, increases in the rate of recurrence are concerning. In addition, there are no guidelines for selecting an eradication regimen for H. pylori recurrence.Materials and MethodsA total of 996 H. pylori‐infected patients treated with proton‐pump inhibitor‐based triple eradication therapy between 2017 and 2022 were enrolled in the study, and successful eradication therapies were confirmed by the 13C‐urea breath test. When retested within 1 year after successful eradication, analysis related to recrudescence was performed, and when retested after 1 year, analysis related to reinfection was performed. We reviewed the medical records and treatment outcomes of patients with H. pylori reinfection after successful eradication.ResultsThe recrudescence rate was 3.9% (9/228), and the reinfection rate was 3.7% (36/970 person‐year). The frequency of reinfection reached 5.9% per person‐year within the first 24 months and 2.0%–2.4% per person‐year thereafter. In multivariate factor analysis, reinfection was significantly higher in patients with non‐ulcer dyspepsia (p < 0.01). At first‐line therapy for reinfection, the eradication rate of standard triple therapy (STT) was 50.0% (16/32). The eradication rate of second‐line bismuth quadruple therapy was 81.3% (13/16), and levofloxacin‐based rescue therapy was 66.7% (2/3).ConclusionRe‐treatment of patients with H. pylori reinfection with STT had limited efficacy. Prospective research is needed to determine whether patients with non‐ulcer dyspepsia are vulnerable to reinfection.

Publisher

Wiley

Subject

Infectious Diseases,Gastroenterology,General Medicine

Reference24 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3